Open, Temporarily Closed
Phase II Trial of Intravesical Gemcitabine and MK-3475 (Pembrolizumab) in the Treatment of Patients with BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
07/19/17, no new patients may register (Step 1) to the NF2 Grade I or Grade II/III cohorts.
(Click for More Info)
Effective 06/26/2020, new patient registration (Step 1) of A031803 is temporarily suspended.